Mounjaro vs Zepbound: Complete Cost Comparison (2026)

Same active ingredient. Same manufacturer. Same injection device. Wildly different insurance paths and out-of-pocket costs. Here's the full 2026 pricing breakdown.

They're the Same Medication

This is the most important thing to understand about the Mounjaro vs. Zepbound comparison: they are pharmacologically identical. Both contain tirzepatide, a dual GIP/GLP-1 receptor agonist. Both are manufactured by Eli Lilly at the same facilities. Both use the same KwikPen auto-injector. Both come in identical dose strengths (2.5mg through 15mg). They produce the same effects, the same side effects, and the same weight loss outcomes.

The only difference is what the FDA approved each one to treat. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and obstructive sleep apnea. This label difference creates entirely separate insurance coverage pathways, which is where the cost divergence begins.

Full Price Breakdown by Dose

*Journey Program pricing requires refilling within 45 days of prior delivery. LillyDirect vials are single-dose glass vials requiring a syringe, not pre-filled pens. Mounjaro does not have a dedicated manufacturer cash-pay program comparable to LillyDirect for Zepbound.

Insurance Coverage: Where the Real Savings Happen

If you have commercial insurance and qualify for a manufacturer savings card, both Mounjaro and Zepbound can cost as little as $25/month. But getting coverage approved is where the experience diverges significantly.

Mounjaro Insurance Path

Approximately 70–85% of commercial insurance plans cover Mounjaro for type 2 diabetes. The prior authorization process is relatively straightforward if you have a T2D diagnosis. Most plans require documented HbA1c levels and evidence that first-line treatments (like metformin) haven't adequately controlled blood sugar. Medicare Part D covers Mounjaro for diabetes, and the Lilly Savings Card brings commercial copays down to $25/month (up to $100/month savings).

Zepbound Insurance Path

Coverage for Zepbound (weight management indication) is significantly harder to get. Prior authorization typically requires documented BMI of 30+ (or 27+ with a weight-related comorbidity), evidence of prior lifestyle intervention, and sometimes a failed trial of a cheaper weight-loss medication first. Many commercial plans still exclude weight-loss medications entirely. However, Zepbound's sleep apnea indication (approved late 2024) provides an alternative coverage pathway for patients with moderate-to-severe OSA.

Who Wins in Each Scenario

The Compounded Alternative

For patients who can't access either brand at an affordable price, compounded tirzepatide offers the same active ingredient at $149–$399/month through licensed telehealth providers. This is the practical option for most cash-paying patients, especially those on government insurance who are excluded from manufacturer savings programs.

Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Compounded tirzepatide is not a generic version of Mounjaro or Zepbound.

Switching Between Mounjaro and Zepbound

Because the active ingredient is identical, switching between Mounjaro and Zepbound is seamless. There's no transition period, no dose adjustment needed, and no clinical risk. Your prescriber simply writes a new prescription for the other brand at the same dose you're currently using. Patients commonly switch for insurance changes, supply availability during shortages, or cost optimization as different savings programs come and go.

The Verdict

There is no pharmacological reason to prefer one over the other. The choice between Mounjaro and Zepbound is entirely about cost and access. If you have a diabetes diagnosis with insurance coverage, Mounjaro is almost certainly cheaper. If you're paying cash for weight management, Zepbound through LillyDirect offers the best brand-name pricing. And if budget is the primary concern, compounded tirzepatide provides the same active ingredient at 60–80% less than either brand.